Disclosures
Alexandra Durr, MD, PhD
| Scientific Advisory Boards | |
| I serve on the SAB of Wavelife, Triplet Therapeutics and Minoryx. | |
| Editorial Boards | |
| (1) Neurology Genetics, associated editor, (2)Journal of Huntington’s Disease, associated editor; (3) International Advisory Committee for Jama Neurology, associated editor | |
| Patents | |
| “Anaplerotic therapy of Huntington disease and other polyglutamine diseases”, BIO06353 Mochel/Durr (EP 06291873.5, 12/4/2006) | |
| Consultancies | |
| (1) F.Hoffmann La Roche, (3) Wavelife | |
| Research Support, Government Entities | |
| READISCA National Institut of Health (RO1) 2018-2022 AAPG ANR 2017: Restoring brain cholesterol metabolism: Development of clinical Gene therapy for Huntington's disease (HDcyp) U01 NS104326-02, board member, 2018-2023 | |
| Royalty Payments, Technology or Inventions | |
| “Anaplerotic therapy of Huntington disease and other polyglutamine diseases”, BIO06353 Mochel/Durr (EP 06291873.5, 12/4/2006) | |